

CLAIMS

1. A healing composition containing at least one non-fibrotic growth factor in combination with a pharmaceutically acceptable carrier.
2. A composition according to claim 1, wherein the non-fibrotic growth factor comprises TGF β -3.
3. A composition according to claim 1 or claim 2, wherein the non-fibrotic growth factor comprises FGF.
4. A composition according to any preceding claim, comprising anti-fibrotic agents.
5. A composition according to claim 4, wherein the anti-fibrotic agents include antibodies to TGF β -1, TGF β -2 and PDGF; binding proteins which prevent TGF β -1, TGF β -2 and PDGF from binding to their receptors by either binding to the growth factor itself, eg. Decorin, Biglycan, or binding to the receptor, eg. peptides containing the receptor binding site sequence; or soluble forms of growth factor receptor or the growth factor binding domains of these receptors or antisense oligonucleotides or ribosymes which act to prevent fibrotic growth factor mRNA translation.

6. A composition according to any preceding claim wherein the non-fibrotic growth factor and/or anti-fibrotic agent(s) are present in the composition in an active form.

7. A composition according to any of claims 1 to 5, wherein the non-fibrotic growth factor and/or anti-fibrotic agent(s) are present in the composition in an inactive form.

8. A composition according to claim 7, wherein inactivation is by encapsulation.

9. A composition according to claim 8, wherein the capsules are degradable by an external stimulus to release the active form when required.

10. A composition according to claim 9, wherein the external stimulus includes UV light, ultrasound, in vivo enzymes or heat.

11. A composition according to claim 7, wherein inactivation is by the molecular addition of a binding molecule which is detachable when required by an external stimulus including UV light, ultrasound, in vivo enzymes or heat.

12. A composition according to any preceding claim, wherein the non-fibrotic growth factor is present in an inactive form, for example, as a precursor, and is activated upon contact with tissue containing the natural cleavage enzymes required to convert the precursor into its active form.
13. A composition according to claim 1, wherein the carrier comprises a neutral sterile cream, gel, aerosol or powder for topical application.
14. A composition according to claim 1, wherein the carrier comprises a patch or a sterile dressing or an absorbable dressing for topically covering a wound.
15. A composition according to claim 1, wherein the carrier comprises a sterile solution for irrigation, injection or inhalation.
16. A composition according to claim 1, wherein the carrier comprises a tablet, capsule, and the like, for enteral administration.
17. A composition according to claim 1, wherein the carrier comprises a biopolymer, for example collagen, hyaluronic acid or polymer, for contacting or implanting into the wound/fibrotic lesion so as to allow release of

the active agents slowly or quickly and for to be active in situ.

18. A method of preparation of a pharmaceutical healing or anti-fibrotic composition containing at least one non-fibrotic growth factor for topical application in a cream, gel, powder, aerosol, patch or dressing, biopolymer or polymer implant, delay or slow release system or in a solution for irrigation, injection or inhalation, or in a tablet or capsule for enteral administration.

19. A method of inhibiting fibrosis during the healing of wounds and other fibrotic diseases, disorders or conditions, comprising administering to a host suffering from tissue wounding or these fibrotic conditions, at least one non-fibrotic growth factor.